Trial Profile
NN1250-3585: A Trial Investigating the Efficacy and Safety of NN1250 Compared to Insulin Detemir in Subjects With Type 1 Diabetes Mellitus in a Basal/Bolus Treatment Regimen
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin aspart; Insulin detemir
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms BEGIN; BEGIN-BB-T1; NN1250-3585
- Sponsors Novo Nordisk
- 04 Jul 2012 New source identified and integrated: United Kingdom Clinical Research Network.
- 17 Mar 2012 This trial is recruting in England (Parent trial: EudraCT2009-011672-29).
- 17 Mar 2012 Actual initiation date changed from Feb 2010 to Nov 2009 as reported by European Clinical Trials Database (Parent trial: EudraCT2009-011672-29).